A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
A phase 3 trial of Trastuzumab rezetecan, Docetaxel, Trastuzumab in her2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
Overview
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer is a phase 3 interventional study registered as NCT07196774 by Jiangsu HengRui Medicine Co., Ltd., with 740 participants enrolled, started 2025-10-23 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-A1811 for Injection, Docetaxel injection, Trastuzumab Injection, Carboplatin for Injection, Pertuzumab Injection. Conditions listed: Early-stage or Locally Advanced HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Trastuzumab rezetecan, Pertuzumab, Docetaxel, Trastuzumab.
- TrialA Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Shares Trastuzumab rezetecan, Pertuzumab, Trastuzumab, Jiangsu Hengrui Pharmaceuticals.
- TrialA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea
Shares Pertuzumab, Docetaxel, Trastuzumab, Carboplatin.
- TrialA Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Shares Pertuzumab, Docetaxel, Trastuzumab, Carboplatin.
- TrialA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M
Shares Pertuzumab, Docetaxel, Trastuzumab, HER2-positive breast cancer.
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab rezetecan, Trastuzumab, Jiangsu Hengrui Pharmaceuticals.
- TrialHER2CLIMB-05
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
- TrialA Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, HER2-positive breast cancer.